Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Reduction of risk of NSAID-associated gastric ulcers in patients at continued risk.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily.
* **NSAID-associated gastric ulcers:** 40 mg orally once daily, duration varies based on healing.
* **Pathological hypersecretory conditions:** Starting dose 40 mg orally twice daily, may be increased as needed. Doses up to 240 mg daily have been administered.
## Pediatric Dosing
* **Erosive esophagitis (12 years and older):** 40 mg orally once daily for up to 8 weeks.
* **GERD (5 years and older):** 20 mg to 40 mg orally once daily for up to 8 weeks.
* **Note:** Dosing for children younger than 5 years is not established.
## Dose Adjustments
No dose adjustment is typically required for patients with hepatic or renal impairment, though caution is advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use of PPIs is associated with an increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **Certain HIV protease inhibitors (e.g., atazanavir, nelfinavir):** Concomitant use is not recommended as decreased plasma concentrations may occur.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **Drugs that rely on gastric pH for absorption (e.g., ketoconazole, itraconazole, iron salts):** PPIs may decrease absorption.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremors, seizures, arrhythmias).
* Monitor for signs of *Clostridium difficile* infection.
* Consider vitamin B12 levels with prolonged therapy.
* Monitor bone mineral density in patients at risk for osteoporosis.
## Clinical Pearls
* Administer 30 minutes before a meal.
* Do not crush or chew delayed-release formulations.
* For IV administration, follow specific reconstitution and infusion guidelines.
* Long-term use should be reserved for appropriate indications and periodically re-evaluated.
***
*This information is intended for healthcare professionals and is not a substitute for clinical judgment. Always consult the most current prescribing information and relevant guidelines before initiating or modifying therapy.*
